T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$1.66B |
| 2 |
KLA
KLAC
|
+$1.39B |
| 3 |
T-Mobile US
TMUS
|
+$1.38B |
| 4 |
Eli Lilly
LLY
|
+$1.37B |
| 5 |
CSX Corp
CSX
|
+$1.18B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$4.2B |
| 2 |
Microsoft
MSFT
|
+$3.24B |
| 3 |
Amazon
AMZN
|
+$2.75B |
| 4 |
Netflix
NFLX
|
+$2.53B |
| 5 |
Apple
AAPL
|
+$2.48B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 35.66% |
| 2 | Financials | 11.78% |
| 3 | Healthcare | 11.44% |
| 4 | Consumer Discretionary | 10.75% |
| 5 | Communication Services | 10.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2501
American Public Education
APEI
$828M
| $384K | ﹤0.01% |
10,150
+944
| +10% | +$33.8K |
|
|
NAGE
2502
Niagen Bioscience
NAGE
$241M
| $384K | ﹤0.01% |
60,342
+3,215
| +6% | +$22.4K |
|
2503
Hyster-Yale Materials Handling
HY
$617M
| $383K | ﹤0.01% |
12,867
+3,525
| +38% | +$116K |
|
2504
Hawthorn Bancshares
HWBK
$277M
| $382K | ﹤0.01% |
10,937
| – | – |
|
2505
Excelerate Energy
EE
$1.12B
| $381K | ﹤0.01% |
13,572
+1,364
| +11% | +$36.9K |
|
2506
SPDR Gold Trust
GLD
$142B
| $381K | ﹤0.01% |
960
-375
| -28% | -$143K |
|
|
CBL
2507
CBL Properties
CBL
$1.78B
| $380K | ﹤0.01% |
10,260
+86
| +0.8% | +$2.81K |
|
2508
Tyra Biosciences
TYRA
$1.49B
| $380K | ﹤0.01% |
14,432
+1,631
| +13% | +$30K |
|
2509
Wabash National
WNC
$509M
| $380K | ﹤0.01% |
43,909
+7,931
| +22% | +$69.2K |
|
2510
Compass Therapeutics
CMPX
$407M
| $379K | ﹤0.01% |
70,488
+13,900
| +25% | +$64.2K |
|
2511
Genie Energy
GNE
$386M
| $379K | ﹤0.01% |
27,435
+4,037
| +17% | +$59.4K |
|
2512
Orrstown Financial Services
ORRF
$855M
| $379K | ﹤0.01% |
10,687
+880
| +9% | +$30.7K |
|
2513
Clean Energy Fuels
CLNE
$395M
| $378K | ﹤0.01% |
179,822
+10,116
| +6% | +$24.7K |
|
2514
Daily Journal
DJCO
$828M
| $378K | ﹤0.01% |
775
+79
| +11% | +$35.1K |
|
2515
Maravai LifeSciences
MRVI
$861M
| $377K | ﹤0.01% |
115,993
| – | – |
|
2516
Thryv Holdings
THRY
$96.9M
| $376K | ﹤0.01% |
62,143
+15,200
| +32% | +$120K |
|
|
KALV
2517
DELISTED
KalVista Pharmaceuticals
KALV
| $374K | ﹤0.01% |
23,118
+3,138
| +16% | +$41.6K |
|
2518
Marcus & Millichap
MMI
$1.2B
| $374K | ﹤0.01% |
13,669
+1,038
| +8% | +$30K |
|
|
MOFG
2519
DELISTED
MidWestOne Financial Group
MOFG
| $373K | ﹤0.01% |
9,678
+1,050
| +12% | +$38.3K |
|
2520
Kura Sushi USA
KRUS
$646M
| $372K | ﹤0.01% |
7,092
+1,630
| +30% | +$88.9K |
|
2521
Blend Labs
BLND
$367M
| $371K | ﹤0.01% |
121,961
+7,368
| +6% | +$23.5K |
|
2522
Equity Bancshares
EQBK
$1.07B
| $371K | ﹤0.01% |
8,307
+862
| +12% | +$36.9K |
|
2523
GrafTech
EAF
$203M
| $368K | ﹤0.01% |
23,688
+5,050
| +27% | +$76.8K |
|
2524
ClearPoint Neuro
CLPT
$470M
| $367K | ﹤0.01% |
26,791
+1,204
| +5% | +$22.3K |
|
2525
Enliven Therapeutics
ELVN
$4.25B
| $367K | ﹤0.01% |
23,800
-207,504
| -90% | -$4.13M |
|
Similar funds
T. Rowe Price Associates's Q4 2025 Portfolio in Review
As of Q4 2025, T. Rowe Price Associates held 3,154 positions worth $927B, down 0.78% from $935B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
T. Rowe Price Associates's Q4 2025 filing shows 113 new, 1,841 increased, 860 reduced and 65 closed positions. Its largest new stake was Medline Inc: 7,325,104 shares worth $308M. The largest sale was NVIDIA, an estimated $4.2B.
By sector, the portfolio is most concentrated in Technology at 36% of assets, down from 36% a quarter earlier, followed by Financials and Healthcare.
- T. Rowe Price Associates's largest Q4 2025 buy was Medline Inc: 7,325,104 shares worth $308M.
- T. Rowe Price Associates added most to Lam Research in Q4 2025, an estimated $1.66B increase.
- T. Rowe Price Associates's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $4.2B.
- T. Rowe Price Associates fully exited Akero Therapeutics in Q4 2025, selling an estimated $181M.
- T. Rowe Price Associates's ten largest holdings make up 37% of its $927B portfolio in Q4 2025.
- T. Rowe Price Associates opened 113 new positions and closed 65 in Q4 2025.
- T. Rowe Price Associates's portfolio value fell 0.78% quarter-over-quarter to $927B.
Based on T. Rowe Price Associates's 13F filing for Q4 2025, filed 17 Feb 2026.